Navigation Links
Cerulean Pharma's Lead Candidate Selected as a "Top 10 Oncology Project to Watch"

CAMBRIDGE, Mass., Nov. 19, 2012 /PRNewswire/ -- Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that its lead candidate, CRLX101, was named as one of the "Top 10 Oncology Projects to Watch" by an independent panel of experts convened by Elsevier Business Intelligence and the Campbell Alliance.

The panel selected compounds using various criteria, including market size and medical need, development history, supporting science, potential for expansion beyond the initial indications and multi-level partnering opportunities.

As part of this recognition, Christopher Guiffre, senior vice president and chief business officer of Cerulean, will present the CRLX101 opportunity at Windhover's Therapeutic Area Partnerships meeting taking place on November 28 through 30, 2012, at the Westin Copley in Boston. Mr. Guiffre's presentation will occur on Thursday, November 29 at 1:40 p.m. Eastern Time.

"Cerulean's nanopharmaceuticals dynamically target tumors by entering through the large pores associated with blood vessels leading to tumors and releasing their drug inside the tumor over time," said Oliver Fetzer, Ph.D., president and chief executive officer of Cerulean. "This approach, which relies not on the patient's genetic profile but on a characteristic of blood vessels common to many tumors, allows us to evaluate CRLX101 in multiple tumor types as a monotherapy and in combination with Avastin®."

About CRLX101

CRLX101 is an investigational anti-cancer agent that is a dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1 alpha (HIF-1α). CRLX101 is designed to concentrate in tumors, prolonging drug exposure at the site of action. Significant anti-tumor activity has been observed across a wide range of cancers in animal models. CRLX101 is in Phase 2 clinical development. More information can be found at

About Cerulean Pharma Inc.

Cerulean Pharma Inc. is a clinical-stage company specializing in the development of dynamically tumor-targeted nanopharmaceuticals. Cerulean is applying its proprietary nanopharmaceutical platform to advance a new class of therapeutic agents to address significant unmet medical needs. With an initial focus in oncology, the Company's technology platform can be applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs. Cerulean is privately financed and funded by experienced healthcare investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, Bessemer Venture Partners, and CVF, LLC. Cerulean is located in Cambridge, Massachusetts. For more information, please visit the Company's website at

Media Contacts:
Schwartz MSL
Benjamin Navon/Kathy Vigneault
+1 781-684-0770


SOURCE Cerulean Pharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
2. ePharmaSolutions Launches an Innovative Patient Recruitment Application for Windows 8
3. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
4. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
5. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
7. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
8. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
9. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
10. New Candidate Drug Stops Cancer Cells, Regenerates Nerve Cells
11. Chimerix Signs Worldwide License Agreement With Merck For CMX157, A Novel Candidate For The Treatment Of HIV
Post Your Comments:
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
Breaking Medicine News(10 mins):